Press Release RSS Feed (opens in new window)

Press Releases

Press release year list 2026 2025 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015 2014
March 31, 2026
Bristol Myers Squibb Evolves and Expands Standing in the Gaap to Advance More Equitable Care in Multiple Myeloma as Program Marks Ten Years
March 29, 2026
Bristol Myers Squibb Presents Positive Results from Phase 3 SCOUT-HCM Trial Demonstrating Efficacy and Safety of Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
March 28, 2026
Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)
March 23, 2026
Bristol Myers Squibb Reinforces Leadership in oHCM with New Camzyos (mavacamten) Data at American College of Cardiology Annual Scientific Session & Expo 2026 (ACC.26)
March 20, 2026
Bristol Myers Squibb Transforms the Classical Hodgkin Lymphoma Treatment Paradigm with Expanded U.S. and EMA Approvals for Opdivo® (nivolumab)
March 19, 2026
Bristol Myers Squibb to Report Results for First Quarter 2026 on April 30, 2026
March 9, 2026
Bristol Myers Squibb Announces Positive Phase 3 Results from the SUCCESSOR-2 Study of Oral Mezigdomide in Relapsed or Refractory Multiple Myeloma
March 6, 2026
U.S. FDA Approves Bristol Myers Squibb’s Sotyktu® (deucravacitinib) for the Treatment of Adults with Active Psoriatic Arthritis
March 2, 2026
Bristol Myers Squibb Announces Dividend
February 26, 2026
SystImmune and Bristol Myers Squibb Highlight Positive Phase III Interim Topline Results for izalontamab brengitecan (Iza-bren) in Previously Treated Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer
February 23, 2026
Bristol Myers Squibb to Participate in the TD Cowen 46th Annual Health Care Conference
February 23, 2026
Bristol Myers Squibb Announces Positive Top-Line Results from Registrational Phase 2 Study of Luspatercept in Adults with Alpha (α)-Thalassemia
February 17, 2026
U.S. Food and Drug Administration Accepts Bristol Myers Squibb's New Drug Application for Iberdomide in Patients with Relapsed or Refractory Multiple Myeloma
February 5, 2026
Bristol Myers Squibb Reports Fourth Quarter and Full-Year Financial Results for 2025
February 4, 2026
Bristol Myers Squibb Teams Up with Kasey Keller to Share His Lymphoma Journey with Breyanzi
February 3, 2026
Bristol Myers Squibb Introduces "Change the Target. Change What’s Possible.” to Highlight Unmet Needs in Cardiovascular and Thromboembolic Care
January 20, 2026
Bristol Myers Squibb Announces Collaboration with Microsoft to Advance AI-Driven Early Detection of Lung Cancer
January 12, 2026
Bristol Myers Squibb Announces Positive Topline Results from Phase 3 SCOUT-HCM Trial Evaluating Camzyos (mavacamten) in Adolescents with Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)
January 2, 2026
Bristol Myers Squibb to Present at J.P. Morgan’s 44th Annual Healthcare Conference